Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan;40(1):e5-e7.
doi: 10.1111/jdv.20698. Epub 2025 May 19.

SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata

Ziad Reguiai  1 , Leila Asfour  2 , Delphine Staumont-Sallé  3 , Ángela Hermosa-Gelbard  4 , Andrea Sechi  5 , Dalia Wajsbrot  6 , Rahmat Ishowo-Adejumo  7 , Deborah Woodworth  7 , Alexandre Lejeune  8
Affiliations

SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata

Ziad Reguiai et al. J Eur Acad Dermatol Venereol. 2026 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Z Reguiai: Investigator, advisory board member or speaker for AbbVie, Almirall, Amgen, Incyte, Eli Lilly, LEO Pharma, Novartis, Pfizer, Sanofi and UCB. L Asfour: Principal investigator for AbbVie and Sanofi, consultant for AbbVie, consultant and speaker for L'Oreal, speaker for Pfizer. President of the British Hair and Nail Society, member of the Alopecia Areata Guidelines Development Group and the Therapeutics & Guidelines BAD Subcommittee. D Staumont‐Sallé: Investigator and/or consultant and/or speaker for AbbVie, Almirall, Amgen, AstraZeneca, Eli Lilly, Galderma, GSK, Leo Pharma, Novartis, Pfizer, Sanofi‐Regeneron and UCB. Á Hermosa‐Gelbard: Principal investigator for Pfizer. Investigator for Concert. Investigator for Lilly. Speaker for Lilly. Advisor and speaker for Pfizer. A Sechi: Received honoraria from Pfizer, Novartis, DS Laboratories, Cantabria Labs Difa Cooper and Eli Lilly. D Wajsbrot, R Ishowo‐Adejumo, D Woodworth and A Lejeune: employees of Pfizer Inc. and hold stock or stock options in Pfizer Inc.

Figures

FIGURE 1
FIGURE 1
SALT score distribution for participants who received daily ritlecitinib 50 mg without a loading dose in ALLEGRO‐2b/3 and ALLEGRO‐LT. Link to interactive dynamic plot: https://datahub.pfizer.com/salt‐distribution.
See this image and copyright information in PMC

References

    1. King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double‐blind, multicentre, phase 2b‐3 trial. Lancet. 2023;401(10387):1518–1529. 10.1016/s0140-6736(23)00222-2 - DOI - PubMed
    1. Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, et al. Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long‐term phase 3 clinical studies in alopecia areata. Br J Dermatol. 2025;192(2):215–227. 10.1093/bjd/ljae365 - DOI - PubMed
    1. King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al. Integrated safety analysis of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25(2):299–314. 10.1007/s40257-024-00846-3 - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources